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REVIEW
Neuropsychological deficits in frontotemporal dementia and
Alzheimer’s disease: a meta-analytic review
A D Hutchinson, J L Mathias
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We sought to identify the cognitive tests that best discriminate
between Alzheimer’s disease (AD) and frontotemporal
dementia (FTD). A comprehensive search of all studies
examining the cognitive performance of persons diagnosed
with AD and FTD, published between 1980 and 2006, was
conducted. Ninety-four studies were identified, comprising
2936 AD participants and 1748 FTD participants. Weighted
Cohen’s d effect sizes, percentage overlap statistics, confidence
intervals and fail-safe Ns were calculated for each cognitive test
that was used by two or more studies. The most discriminating
cognitive tests were measures of orientation, memory,
language, visuomotor function and general cognitive ability.
Although there were large and significant differences between
groups on these measures, there was substantial overlap in the
scores of the AD and FTD groups. Age, education, years since
diagnosis and diagnostic criteria did not significantly contribute
to the group differences. Given the large overlap in the test
performance of persons diagnosed with AD and FTD, cognitive
tests should be used cautiously and in conjunction with a
medical history, behavioural observations, imaging and
information from relatives when making differential diagnoses.
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D
ementia is an important social and health
issue in our ageing population, with the
prevalence of Alzheimer’s disease (AD) in
the USA predicted to increase by approximately
300% by 2050.1 Two forms of dementia, AD and
frontotemporal dementia (FTD), and their differ-
ential diagnosis using cognitive tests, are
addressed in the current study.
AD is the most prevalent and well researched
type of dementia.2 People with AD usually exhibit
a progressive decline in general cognitive function-
ing,3 together with acalculia, apraxia, visuospatial
problems, poor orientation and impaired language
comprehension, attention and memory.2 4–6
Memory problems are one of the earliest symp-
toms, with the ability to learn and retrieve
information being affected initially and impair-
ments in recognition memory developing later.2 3 7
FTD, on the other hand, is variously referred to
as Pick disease, dementia of the frontal type,
frontal lobe dementia of the non-Alzheimer’s type,
frontotemporal lobar degeneration, semantic
dementia and progressive non-fluent aphasia.8 9
FTD refers to a group of degenerative dementias
that are characterised by atrophy of the fronto-
temporal cortex.5 8 10 Although people with FTD
may also experience memory problems, these
deficits are more frequently associated with a
tendency to respond impulsively and a failure to
monitor performance.5 9 As with AD, retrieval of
information from memory is affected. However,
unlike AD, the provision of cues can assist
performance.9 Persons with FTD also have more
impairments in executive functioning2–6 9 11 12 and
language (eg, inability to repeat, stereotyped
phrases, reduced speech).5 7 9 Finally, although
general cognitive ability may be unaffected in the
early stages of FTD, it does decline over time.4 12
While definitive diagnoses of AD and FTD can
only be made at autopsy, interim diagnoses usually
take into account the base rates of the disorder,
clinical criteria, medical history, physical examina-
tion, brain imaging and neuropsychological assess-
ments.6 10 12 Unfortunately, the diagnosis of FTD
can be difficult because of its insidious and gradual
onset8 9 and can also be misdiagnosed as AD.13 14
However, accurate differential diagnosis has
become increasingly important because of the
recent availability of pharmacological treatments
that temporarily improve the cognitive and func-
tional abilities of people with AD.15–21 Moreover,
delays in the commencement of these treatments
significantly reduce their benefits,19 22 highlighting
the importance of early and accurate diagnosis. In
contrast, no specific pharmacological treatments
currently exist for FTD, although research is
continuing.23
If neuropsychological assessments are to make a
valuable contribution to the diagnosis of dementia,
clinicians need to know what cognitive tests best
discriminate between the different types of
dementia. Despite the differing clinical character-
istics of these two disorders and the wide variety of
tests that have been researched with AD and FTD
samples, research has yielded inconsistent find-
ings, both in terms of the cognitive constructs (eg,
memory, language) and the specific tests that
appear to differentiate between AD and FTD.14 24–33
These inconsistencies may, in part, be due to
methodological differences in the research litera-
ture, such as variations in the participants’ age,
time since diagnosis, stage of dementia and
diagnostic criteria. A recent narrative review of
the literature concluded that there are no tests that
Abbreviations: ACE, Addenbrooke’s Cognitive
Examination; AD, Alzheimer’s disease; AVLT, Auditory
Verbal Learning Test; FTD, frontotemporal dementia;
MMSE, Mini-Mental State Examination; Nfs, fail safe N;
%OL, percentage overlap; WAB, Western Aphasia Battery;
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accurately discriminate between AD and FTD.34 However, a
review of this type cannot adequately consolidate and analyse
the data or reconcile differences in methodology.35 A meta-
analysis, in contrast, provides an objective and quantitative
means by which to directly compare existing findings, thereby
providing an important addition to the existing literature.36 37
The current study therefore undertook a meta-analytic review
of research that has compared the cognitive performance of AD
and FTD samples in order to identify the tests that best
discriminate between AD and FTD and, therefore, are most
likely to be of use when making a differential diagnosis.
METHOD
Literature search and inclusion criteria
A comprehensive search of the PubMed and PsycINFO
electronic databases from January 1980 to November 2006
was undertaken to identify all published studies that assessed
the cognitive functioning of AD and FTD samples. The key
search terms that were used to capture relevant articles are
shown in table 1. The bibliographies of relevant papers were
also examined for additional references. To be selected for the
current meta-analysis, a study had to meet the following
inclusion criteria: (1) it examined groups of participants with
AD and FTD (excludes case studies), (2) cognitive tests were
administered to both groups (excludes rating scales and
questionnaires), (3) the cognitive tests were not used for the
diagnosis and classification of participants into the AD and FTD
groups (ie, a test could not be used as both a dependent and
independent variable), (4) statistical data enabling the calcula-
tion of Cohen’s d effect sizes38 was provided (eg, mean and SD, t
tests or one way F tests) and (5) it was published in English.
This literature search yielded 2785 potentially relevant
studies, 93 of which met all of the inclusion criteria. These 93
studies used a total of 136 different cognitive tests which, in
turn, yielded results for 1019 different test scores (ie, some tests
yielded multiple scores). A total of 114 of these test scores were
used by more than one study and were, therefore, included in
the current meta-analysis. Of the studies that did not meet one
or more of the inclusion criteria, 2687 did not undertake
cognitive testing with the AD and FTD samples, 67 did not
provide data that would enable the calculation of effect sizes
and 96 studies only used cognitive tests for the diagnosis and
classification of participants. An additional paper39 was
excluded because it presented data that had been reported in
another publication that was to be included in this study.40 This
was done to ensure that the data were independent, as meta-
analytic techniques assume that a single study only contributes
one score to the calculation of a particular effect size.41 Finally,
one publication was treated as two studies because data were
provided for separate samples in the one article.42 Thus 94
independent studies were effectively included in the final meta-
analysis.
Data collection and preparation
Consistent with the most commonly used diagnostic criteria for
AD,43 the Mini-Mental State Examination (MMSE) was fre-
quently used when diagnosing dementia. The MMSE was
therefore only included as a dependent variable in the current
meta-analysis when groups were formed on the basis of a post-
mortem diagnosis of AD or FTD dementia. However, where
provided, MMSE scores are reported as descriptive data for the AD
and FTD samples (refer to table 2). In addition, whenever it was
not clear whether a particular cognitive test was used to diagnose
dementia and classify participants, this test was excluded from the
meta-analysis in order to ensure that a measure was not used as
both a dependent and independent variable.
Where test scores were obtained from different editions of
the same test (eg, Wechsler Adult Intelligence Scales), these
were combined for the purposes of calculating mean effect
sizes. Care was taken to ensure that the scores for a given test
provided independent measures of performance. Thus sub-
scores and total scores from a test could not both be used in the
calculation of an effect size. Similarly, where a study provided
multiple scores for the same test (eg, easy and hard versions of
a geometric figure task44), effect sizes were calculated for each
score and then averaged to provide a single effect size for that
study; thereby ensuring that a study only contributed one score
to the calculation of a mean effect size. This was not necessary
when effect sizes for different scores from the same test were
reported separately (eg, speed and accuracy).
All tests were broadly grouped into seven cognitive categories
in order to organise the findings of this meta-analysis. Lezak et
al45 and Spreen and Strauss46 were consulted for this purpose.
These categories are: orientation and attention, memory,
construction, verbal abilities and language, concept formation
and reasoning, executive functioning and motor tasks, and
general ability and intelligence.
Effect size calculations and analyses
Cohen’s d38 effect sizes were calculated to measure the extent of
the difference between the scores of the AD and FTD samples,
where a small effect size is defined as d = 0.2, a medium effect
as d = 0.5 and a large effect as d = 0.8. To put this into
perspective, an effect size of 0.5 indicates that the scores for the
two groups differ by half of a pooled standard deviation. The
percentage overlap between the scores of the two groups can
also be calculated from an effect size47; d = 0 equates to 100%
overlap (ie, the groups are indistinguishable), d = 1.0 equates to
45% overlap and d = 3.0 equates to less than 5% overlap in the
groups’ scores. These statistics are provided for all effect sizes in
order to facilitate their interpretation, especially with regard to
their potential for assisting with differential diagnosis.
Effect sizes were calculated in a multi-stage process. The first
stage involved calculating effect sizes for each score of every
test that was used by each individual study. When calculating
effect sizes, FTD scores were always subtracted from AD scores.
In most cases, higher test scores indicated better performance.
Therefore, a positive effect size indicates that FTD participants
were more impaired on a given measure than AD participants.
In cases where a higher score indicated greater impairment
than a lower score (eg, errors, speed), the direction of the effect
sizes for these scores was transformed so that a positive effect
size still indicated greater impairment in the FTD group.
Table 1 Key search terms
Alzheimer’s disease Frontotemporal dementia Assessment
Alzheimer’s disease Frontotemporal dementia Diagnosis
Alzheimer* Frontal dementia Screening
Pick’s disease Cognit*
DAT Semantic dementia Neuropsychol*








AD, Alzheimer’s disease; DAT, dementia of the Alzheimer’s type; DFT,
dementia of the frontal type; FLD, frontal lobe dementia of the non-
Alzheimer’s type; FTD, frontotemporal dementia; FTLD, frontotemporal lobe
dementia; PNFA, progressive non-fluent aphasia; PPA, primary progressive
aphasia.
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The effect sizes for all studies that used a particular test score
were aggregated to calculate a mean effect size (and SD).
Whereas mean effect sizes measure the extent (and direction)
of the difference between AD and FTD, the SD indicates the
variation in effect sizes between studies. Before aggregating the
scores from individual studies, each effect size was weighted to
take into account the fact that the reliability of an effect size is
affected by the size of the sample from which it is derived.
According to Lipsey and Wilson,48 the inverse of the variance
provides a better measure of the precision of an effect size than
sample size. Consequently, the inverse of the variance was used
to weight all effect sizes (dw) using the formulae below.
where ES = effect size,
and SE = standard error.
Effect sizes are only reported for tests that were used by two
or more studies because effect sizes that are based on a single
study are not thought to provide a reliable measure of group
differences.41 Ninety-five per cent confidence intervals (CIs) for
these mean effect sizes were additionally calculated in order to
determine their statistical significance. If a CI does not span
zero, this indicates that the true population effect size differs
significantly from zero, indicating that there is a significant
difference between the performance of the AD and FTD groups.
One problem facing all meta-analyses is that studies with
statistically significant results are more likely to be published
and, therefore, more likely to be included in a meta-analysis.
Failure to include unpublished studies with non-significant
results increases the risk of a type 1 error, which may result in
an effect size being overestimated.49 A fail safe N (Nfs) was
therefore calculated, using the method described by
Rosenthal,41 to address this problem. This statistic estimates
the number of unpublished studies, with non-significant
results (ie, small effect) that would be required in order to
call the current findings into question.41 The larger the number,
the more confident we can be in a particular finding.
An additional problem that faces meta-analytic studies (and
qualitative reviews) is that there are methodological differences
between studies that may affect the findings and, therefore, the
effect sizes. The impact of diagnostic certainty was therefore
examined in order to determine whether the research findings
were affected by the criteria that were used to establish









participants Mean SD Range
N 94 2936 31.2 41.1 4.0 236.0 94 1748 18.6 12.6 2.0 67.0
Age (y) 88 2792 70.6 5.1 55.7 79.9 89 1658 64.8 4.6 56.0 78.1
Education (y) 61 1878 11.4 3.0 4.0 16.3 62 1091 11.8 3.0 4.0 17.4
Time since diagnosis (y) 38 1237 3.8 1.5 1.7 9.8 38 752 3.9 1.4 1.3 8.4
MMSE 76 2506 21.4 3.0 8.9 26.6 75 1460 22.7 3.0 13.8 28.7
CDR 20 398 1.2 0.7 0.5 3.5 19 332 1.2 0.9 0.5 4.5
AD, Alzheimer’s disease; CDR, Clinical Dementia Rating scale; FTD, frontotemporal dementia; MMSE, Mini-Mental State Examination.
*The N differs between variables because not all studies provided data for each variable






Cohen’s dw SD dw (95% CI) Min d Max d Nfs %OL Study references
ACE Orientation 2 170 21.08 0.25 (21.43, 20.73) 21.20 20.95 9 41 85 102
ACE Attention 2 170 20.79 0.24 (21.13, 20.45) 20.86 20.71 6 53 85 102
Trails B (errors) 2 62 20.60 0.37 (21.11, 20.09) 20.75 20.20 4 62 74 123
Stroop (word reading/Stroop A) 4 105 0.46 0.45 (0.02, 0.89) 20.40 5.2 5 67 31 60 86 131
Digit Symbol 5 373 20.40 0.33 (20.69, 20.11) 20.67 20.28 5 73 56 62 64 86 94
Modified Trails (connection/min) 4 225 20.38 0.28 (20.66, 20.10) 20.69 20.18 4 73 25 93 97 98
Stroop (number correct—incongruent
trial)
6 358 20.29 0.29 (20.52, 20.06) 20.57 0.41 3 79 28 44 60 93 97 98
Digit Span (overall score) 8 479 0.29 0.34 (0.05, 0.52) 20.47 0.98 3 79 27 29 62 68 86 126 130 134
Corsi Blocks (visual span) 4 166 20.29 0.34 (20.62, 0.04) 20.73 20.06 2 79 29 68 129 130
Trails B (time) 8 233 20.28 0.39 (20.56, 20.01) 20.89 2.39 3 79 60 74 80 108 111 114 123 129
Attentional Matrices 3 99 20.22 0.35 (20.62, 0.18) 20.45 0.27 0 85 68 123 130
Stroop (colour naming/Stroop B) 3 92 0.22 0.40 (20.22, 0.67) 20.39 1.53 0 85 31 60 86
Stroop (interference) 2 70 0.18 0.36 (20.33, 0.68) 20.07 0.49 0 85 88 100
Stroop (errors—incongruent trial) 3 78 0.18 0.40 (20.28, 0.63) 20.13 1.09 0 85 27 80 130
Digit Span (forwards) 13 453 0.14 0.36 (20.06, 0.33) 20.80 2.73 0 92 28 30 60 72 74 78 88 91 110
111 119 123 129
Stroop (time—incongruent trial) 2 40 0.14 0.45 (20.48, 0.77) 20.23 0.37 0 92 27 130
Trails A (time) 5 162 20.12 0.38 (20.46, 0.21) 20.73 0.32 0 92 60 74 86 111 129
Digit Span (backwards) 19 697 0.11 0.35 (20.04, 0.27) 21.16 1.08 0 92 25 28 30 60 67 72 74 77 78 80 88
91 93 97 98 110 111 119 123
ACE, Addenbrooke’s Cognitive Examination; Max d, maximum effect size; Mean dw, mean weighted effect size; Min d, minimum effect size; N, number of studies
contributing to the effect size; Nfs, fail safe N; %OL, per cent overlap between Alzheimer’s disease and frontotemporal dementia groups; SD dw, SD of weighted effect
size; 95% CI, 95% CI for means.
*Effect sizes weighted by the inverse variance.
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dementia type. Every study was given a score according to the
diagnostic criteria that were used to define each of their
samples. As post-mortem neuropathological confirmation of
AD or FTD provides the gold standard for a diagnosis of
dementia, this was given a score of three (NAD = 5, NFTD = 5
studies), while studies using the National Institute of
Neurologic, Communicative Disorders and Stroke-AD and
Related Disorders Association (NINCDS-ADRDA) diagnostic
criteria for AD43 and the Lund and Manchester criteria for FTD50
were given a score of 2 (NAD = 82, NFTD = 74 studies). Studies
that used revised or similar criteria, particularly prior to the
publication of these guidelines, were also given a score of 2.
Finally, a score of 1 was given to studies whose diagnostic
criteria were less rigorous or not clearly specified (NAD = 7,
NFTD = 15 studies). The diagnostic scores for studies therefore
varied between 2 and 6.
The potential influence of three other methodological
variables (participant age, years since diagnosis and education)
was also examined. Mean age, years since diagnosis and years
of education were calculated for each study (eg, MAD+FTDage) for
this purpose. This was done by combining the data from the AD
and FTD groups for that study and weighting it by the sample
sizes of the AD and FTD groups.
While there is considerable confusion within the literature
regarding the best way to analyse the influence of methodo-
logical variables on effect sizes, Steel and Kammeyer-Mueller51
have demonstrated that a weighted least squares (WLS)
multiple regression (using the inverse of the sampling error
variance to weight the multiple regression) is less affected by
the problems of heteroscedasticity and multicollinearity, which
can affect the accuracy of these analyses. Heteroscedasticity
occurs when the distribution of study sample sizes is skewed
(eg, a large number of studies with small samples and few with
very large samples) and multicollinearity occurs when predictor
variables are correlated with one another.51 52 A WLS multiple
regression was therefore conducted, in addition to Pearson r
correlation coefficients, in order to examine these methodolo-
gical variables. Standard errors and confidence intervals for the
results of the WLS multiple regression were adjusted according
to the method outlined by Hedges.53
RESULTS
Participants
The demographic characteristics for the participants in the 94
studies that were included in the current meta-analysis are
shown in table 2. Overall, 4684 participants were included in
this study. Gender was only reported in 69 studies, providing
data for 3480 cases (males: NAD = 917, NFTD = 737; females:
NAD = 1253, NFTD = 573). When the demographic characteristics
of the AD and FTD participants that were included in this meta-
analysis were compared, the FTD participants were found to be
significantly younger (t = 12.59, df = 86, p,0.001), more edu-
cated (t =22.51, df = 60, p = 0.015) and had significantly higher
MMSE scores (t =25.41, df = 74, p,0.001) than the participants
with AD. However, the two groups did not differ significantly in
terms of the time since their diagnosis (t = 0.38, df = 36,
p = 0.709) or Clinical Dementia Rating scores (t = 0.25, df = 18,
p = 0.807).
Five studies had pathological confirmation of AD,54–58 82 used
published criteria,14 25 27–31 40 42 44 59–129 and seven did not specify
diagnostic criteria.130–136 For the diagnosis of FTD, five studies
had pathological confirmation,54–58 74 used published cri-
teria,14 25 27 28 30 31 40 42 44 59–64 66–73 76–105 108–116 118 120–124 126–129 131 14
did not clearly specify the diagnostic criteria29 65 74 75 106 107 117 125
130 132–136 and one study used a combination of clinical observa-
tions and published criteria.119
There were not enough studies reporting data for premorbid
intelligence (n = 6) or scores on the Dementia Rating Scale
(n = 6) to report or analyse this information. Similarly, too few
studies reported information about participants’ current med-
ications (n = 19), much of which was not comparable, to
meaningfully examine this information. Thirty-five studies
reported information regarding the inclusion or exclusion of
depressed participants. However, only six of these provided
scores from depression rating scales.
Cognitive tests
The weighted effect sizes (dw) for all measures (mean, SD, 95%
CI, minimum, maximum), grouped according to test category
(orientation and attention, memory, construction, verbal
abilities and language, concept formation and reasoning,
executive functioning and motor tasks, and general ability
and intelligence) and rank ordered by size, are provided in
tables 3–10. Nfs and the percentage overlap between groups
(%OL) are also provided, as are the number of studies (N) that
used each measure, the number of participants that were
assessed and the study references. The conclusions drawn from
this study are based on the combined interpretation of these
statistics. From a neuropsychological perspective, differential
diagnoses are likely to be more accurate when there are large
group differences (d) and there is limited overlap in the
cognitive profiles (%OL). A clinician would also be more
confident in their decision if the CI did not span zero (ie, groups
differ significantly) and it is unlikely that the possibility of
unpublished findings would draw a diagnosis into question
(Nfs). Thus in order for a measure to be useful for
differentiating between AD and FTD dementia, it had to meet
the following criteria: (i) have a large effect size (ie, dw > 0.8)
and, consequently, a limited degree of group overlap (%OL
,50), (ii) a confidence interval that did not span zero (CIs are
affected by N and SD/range) and (iii) an Nfs score that was
large enough to make it unlikely that there were that number of
unpublished studies with non-significant findings in existence.
As different tests were used with varying frequency, it was
decided that the Nfs should be greater than the number of
published studies that had used the test (ie, Nfs .Nstudies).






Cohen’s dw SD dw(95% CI) Min d Max d Nfs %OL Study references
VOSP position discrimination 2 57 20.70 0.40 (21.25, 20.14) 21.34 0.00 5 57 28 109
VOSP dot counting 3 78 20.68 0.54 (21.29, 20.06) 21.07 0.00 7 57 109 110 120
VOSP object decision 4 109 0.34 0.40 (20.06, 0.73) 20.75 0.99 3 79 78 109 110 120
VOSP cube analysis 4 98 20.23 0.42 (20.64, 0.17) 20.61 0.52 1 85 109 110 119 120
VOSP incomplete letters 4 108 0.04 0.39 (20.35, 0.43) 20.83 0.47 0 100 78 109 110 119
Max d, maximum effect size; Mean dw, mean weighted effect size; Min d, minimum effect size; N, number of studies contributing to the effect size; Nfs, fail safe N; SD
dw, SD of weighted effect size; %OL, per cent overlap between Alzheimer’s disease and frontotemporal dementia groups; VOSP, Visual Object and Space Perception
Battery; 95% CI, 95% CI for means.
*Effect sizes weighted by the inverse variance.
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Overall, the effect sizes ranged from a minimum of 20.05 for
the Judgement of Line Orientation Test to a maximum of 1.39
for the Graded Naming Test. Thus there was considerable
variation in the extent to which the AD and FTD groups
differed on the measures used by the 94 studies that were
included in the current meta-analysis. This is also reflected in
the per cent overlap statistics, which indicate that there was
100% overlap between the AD and FTD groups on the least
discriminating measure (Judgement of Line Orientation Test)
and 32% overlap between the two groups for the most
discriminating measure (Graded Naming Test). Also interesting
is the fact that the cognitive tests reported here were used by
between two (eg, Addenbrooke’s Cognitive Examination (ACE)
subtests, Western Aphasia Battery (WAB) Comprehension) and
43 studies (Category Fluency). Thus while some measures have
been used infrequently, others have been studied very
extensively (eg, Category Fluency, Letter Fluency, Rey
Complex Figure, Boston Naming Test). In terms of the
statistical significance of the effect sizes, as indicated by CIs
that do not span zero, there were 69 effect sizes that differed
significantly from zero.
Of the 18 measures of orientation and attention, only the
ACE orientation score met the study criteria (see table 3). This
measure had a large and significant effect size, reflecting 41%
overlap in the scores of the AD and FTD groups, with the AD
group performing more poorly than the FTD group on this
measure. The Nfs for this measure was also well in excess of the
number of published studies using this measure, suggesting a
high degree of confidence in this finding.
Only five measures of perception were used by two or more
studies and these were all taken from the Visual Object and
Space Perception battery (see table 4). None of these measures
produced large effects, although position discrimination and
dot counting revealed moderate group differences and CIs that
did not span zero. However, these measures were associated
with more than 50% overlap between the two groups and both
had modest Nfs, indicating that the effect sizes could be
reduced to a small effect size if there were 5–7 unpublished
studies that had found small group differences. Therefore, none
of the measures of perception accurately discriminated between
persons with AD and FTD.
Memory was one of the most commonly assessed cognitive
domains. In particular, the Rey Complex Figure Test and the
Logical Memory subtest from the Wechsler Memory Scale
(WMS) were very commonly used (see table 5). The recognition
and delayed recall scores of the Auditory Verbal Learning Test
(AVLT), the delayed recall trial of the Rey Complex Figure task,
the Recognition Memory Test (words), the retention and
delayed recall scores of the Logical Memory subtest from the
WMS, the memory score from the ACE, the delayed recall score
of the Visual Reproduction subtest from the WMS and the total
recall score from the Selective Reminding Test all had large and
significant effect sizes and less than 50% overlap between
groups. Persons with AD performed more poorly than those
with FTD on all of these measures. The delayed recall of the Rey
Complex Figure task, in particular, has been used widely (21
studies) and the Nfs suggest that it is unlikely that this result
would be negated by non-significant unpublished findings. The
recognition score of the AVLT, the Recognition Memory Test for
words, the retention score of the Logical Memory subtest from
the WMS and the memory score of the ACE have been less
widely used and, while acceptable, their Nfs were substantially
lower.
Regarding tests of verbal abilities and language, there were
more tests that fell into this category than any other. Eight of
these test scores yielded large effect sizes, 95% CIs that did not






Cohen’s dw SD dw (95% CI) Min d Max d Nfs %OL Study references
AVLT (recognition) 2 46 21.25 0.59 (22.08, 20.43) 24.0 0.00 11 35
27 134
Rey Complex Figure (recall) 21 783 21.09 0.37 (21.25, 20.93) 26.51 0.07 93 41
25, 27, 29–31, 68, 78, 82, 86, 89, 90, 93, 97, 98, 110, 115, 119, 120, 123, 129,
134
Recognition Memory Test (words) 4 113 21.03 0.41 (21.43, 20.63) 21.46 20.55 17 45
28 82 119 120
WMS Logical Memory (% retention) 3 84 21.00 0.43 (21.48, 20.51) 23.21 20.21 12 45
27 28 31
ACE Memory 2 170 20.92 0.25 (21.27, 20.58) 21.05 20.78 7 48
85 102
WMS Logical Memory (delayed) 10 303 20.90 0.42 (21.16, 20.65) 22.17 0.30 35 48
30 42 56 78 82 86 94 110 124
WMS Visual Reproduction (delayed) 3 95 20.90 0.41 (21.37, 20.44) 21.23 0.48 11 48
56 94 124
Selective Reminding Test (total recall) 2 46 20.89 0.46 (21.53, 20.25) 21.06 20.68 7 48
60 121
AVLT (delayed recall) 5 235 20.87 0.39 (21.21, 20.53) 24.32 20.13 17 48
27 96 101 123 134
AVLT (immediate recall) 5 235 20.76 0.37 (21.09, 20.43) 22.26 20.04 14 53
27 96 101 123 134
CVLT (delayed free recall) 5 224 20.68 0.32 (20.96, 20.40) 21.39 20.49 12 57
87 93 97 98 111
WMS Logical Memory (immediate recall) 11 335 20.63 0.40 (20.86, 20.40) 22.23 0.25 24 62
30, 31, 42, 56, 78, 82, 94, 110, 120, 124
Babcock Story Recall Test 2 74 20.58 0.34 (21.04, 20.11) 20.81 20.23 4 62
68 123
Selective Reminding Test (recognition) 2 46 20.52 0.45 (21.13, 0.10) 20.59 20.42 3 67
60 121
CERAD2NP (delayed recall) 2 193 20.50 0.21 (20.79, 20.21) 20.85 20.35 3 67
70 105
WMS Visual Reproduction (immediate) 3 101 20.48 0.38 (20.91, 20.05) 20.80 20.08 4 67
56 94 124
AMI Personal Semantic Schedule (childhood) 2 52 0.47 0.41 (20.10, 1.04) 0.34 0.59 3 67
60 116
Selective Reminding Test (free recall) 2 46 20.47 0.44 (21.09, 0.14) 20.48 20.47 3 67
60 121
AMI Autobiographical Incidents Schedule (childhood) 2 52 0.37 0.41 (20.20, 0.94) 0.17 0.59 2 73
60 116
AMI Personal Semantic Schedule (recent life) 2 52 20.35 0.43 (20.94, 0.24) 21.25 0.45 1 73
60 116
AMI Personal Semantic Schedule (early adulthood) 2 52 0.34 0.41 (20.23, 0.90) 0.33 0.35 1 79
60 116
CVLT (trial 4) 3 159 0.30 0.30 (20.03, 0.63) 20.10 0.36 2 79
93 97 98
AMI Autobiographical Incidents Schedule (recent life) 2 52 20.25 0.42 (20.83, 0.33) 20.91 0.39 0 79
60 116
CVLT (recognition discrimination) 2 67 20.22 0.36 (20.71, 0.27) 20.46 0.54 0 85
87 93
WMS Logical Memory (score not specified) 4 125 20.20 0.41 (20.59, 0.20) 20.59 0.41 0 85
29 60 89 130
Shopping List (delayed recall) 2 68 0.18 0.37 (20.34, 0.69) 0.04 0.41 0 85
31 86
Recognition Memory Test (faces) 4 113 0.18 0.39 (20.21, 0.56) 20.33 1.06 0 85
28 82 119 120
AMI Autobiographical Incidents Schedule (early adulthood) 2 52 20.16 0.41 (20.73, 0.40) 20.28 20.04 0 85
60 116
Benton Visual Retention Test 3 194 20.16 0.29 (20.49, 0.17) 20.31 0.45 0 85
44 60 74
ACE, Addenbrooke’s Cognitive Examination; AMI, Autobiographical Memory Interview; AVLT, Auditory Verbal Learning Test; CERAD2NP, Consortium to Establish a Registry for Alzheimer’s Disease–
Neuropsychological Battery; CVLT, California Verbal Learning Test; Max d, maximum effect size; Mean dw, mean weighted effect size; Min d, minimum effect size; N, number of studies contributing to the effect size;
Nfs, fail safe N; %OL, per cent overlap between the Alzheimer’s disease and frontotemporal dementia groups; SD dw, SD of weighted effect size; 95% CI, 95% CI for means; WMS, Wechsler Memory Scale (all
editions).
*Effect sizes weighted by the inverse variance.
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span zero and large Nfs statistics, indicating that there were
large and significant group differences on these measures and
that these findings are unlikely to be negated by unpublished
findings (see table 6). Specifically, these measures were: the
Graded Naming Test, Word–Picture Matching, WAB
Spontaneous Speech (fluency), the Pyramids and Palm Trees
(word score, picture score), other picture naming tasks, WAB
Comprehension and WAB Repetition. For all eight verbal
measures, the FTD groups performed more poorly than the
AD group. In addition to these eight measures, there were a
number of other commonly used measures, such as the
Pyramids and Palm Trees (score not specified) and letter
fluency tasks, which showed moderate effect sizes, had 95% CIs
that did not span zero and large Nfs statistics. However,
because the effect sizes for these measures were relatively low
(indicating small to medium differences in the AD and FTD
means), there was an unacceptably high degree of overlap (53%
and 67%, respectively) between the scores for the AD and FTD
groups.
Of the seven measures of construction that were used by two
or more studies, only the Beery Developmental Test of Visual
Motor Integration demonstrated a large group difference, less
than 50% overlap in scores, 95% CIs that did not span zero and
a satisfactory Nfs (see table 7). As with the abovementioned
memory tests, the effect size was negative, indicating that the
AD groups performed more poorly on this task than the FTD
groups.
Despite researchers using a number of different measures of
concept formation and reasoning, none of them showed large
group differences (ie, d .0.8) (see table 8). Indeed, there was
between 57% and 92% overlap in the scores of the AD and FTD
groups on all 12 measures. Commonly used measures, such as
the Wisconsin Card Sorting Test and Raven’s Progressive
Matrices, did not successfully discriminate between AD and
FTD when the findings of all studies that had used these
measures were considered, although the minimum and
maximum effects sizes for these tests indicate that there were
individual studies that reported large effects for these tests.
When the classifications used by Lezak et al45 and Spreen and
Strauss46 were used to group the cognitive tests, there were only
four tests that fell into the category of executive function and
motor performance (see table 9), although other tests that are






Cohen’s dw SD dw (95% CI) Min d Max d Nfs %OL Study references
Graded Naming Test 3 88 1.39 0.44 (0.89, 1.88) 0.61 3.01 18 32
28 78 109
Word–Picture Matching 5 123 1.05 0.44 (0.66, 1.44) 0.37 2.00 21 41
30 79 109 119 120
WAB Spontaneous Speech (fluency) 2 227 1.04 0.20 (0.76, 1.32) 0.48 1.29 8 45
94 124
Pyramids and Palm Trees (words) 5 185 1.02 0.36 (0.71, 1.34) 0.65 1.72 21 45
82 90 114 119 120
Other picture naming tasks 11 291 0.99 0.45 (0.73, 1.26) 20.45 2.93 43 45
30, 60, 82, 88, 109, 110, 112, 115, 119, 133, 136
Pyramids and Palm Trees (pictures) 4 116 0.90 0.40 (0.51, 1.30) 0.29 1.48 14 48
78 82 119 120
WAB Comprehension 2 35 0.88 0.51 (0.18, 1.59) 0.42 1.27 7 48
75 111
WAB Repetition 3 247 0.81 0.23 (0.55, 1.07) 0.32 1.28 9 53
75 94 124
Pyramids and Palm Trees (score not
specified or average of words and
pictures)
5 123 0.79 0.43 (0.41, 1.17) 20.39 1.31 15 53
28 30 80 115 136
WAB Naming (object naming) 3 247 0.78 0.23 (0.51, 1.04) 0.30 1.11 9 53
75 94 124
WAB Aphasia Quotient 2 81 0.77 0.33 (0.31, 1.22) 0.55 1.61 6 53
75 94
WAB Praxis 2 158 0.71 0.23 (0.39, 1.04) 0.69 0.88 5 57
75 124
WAB Naming (responsive speech) 3 247 0.70 0.23 (0.44, 0.96) 0.33 0.85 7 57
75 94 124
WAB Naming (sentence completion) 3 247 0.65 0.23 (0.39, 0.91) 0.30 0.79 7 57
75 94 124
WAIS Vocabulary 3 325 0.62 0.30 (0.28, 0.96) 0.40 0.77 6 62
62 86 94
WAB Reading and writing (writing) 2 152 0.62 0.24 (0.29, 0.95) 0.47 0.64 4 62
75 124
WAB Comprehension (yes/no) 2 227 0.57 0.14 (0.30, 0.84) 0.40 0.63 4 62
94 124
WAB Spontaneous Speech (content) 2 227 0.57 0.19 (0.30, 0.84) 0.54 0.64 4 62
94 124
ACE Naming 2 170 0.55 0.24 (0.21, 0.88) 0.36 0.76 3 62
85 102
Letter Fluency 39 1494 0.53 0.36 (0.42, 0.65) 20.71 2.19 65 67
25, 27, 29231, 42, 56, 60, 64, 65, 67269, 72, 74, 76, 78, 80,
84, 86, 88, 92, 93, 96298, 100, 101, 110, 111, 114, 1182121,
123, 126, 129




2 227 0.47 0.19 (0.21, 0.74) 0.34 0.53 3 67
94 124
ACE Language 2 170 0.39 0.24 (0.06, 0.72) 0.12 0.70 2 73
85 102
Verb Similarity Task 2 69 0.39 0.35 (20.10, 0.87) 0.30 0.51 2 73
108 114
WAIS Information 3 330 0.35 0.28 (0.04, 0.67) 0.31 0.52 2 73
60 62 94
Sentence Comprehension 4 221 0.32 0.28 (0.04, 0.60) 20.44 0.54 2 79
93 94 97 98
ACE Verbal fluency (letter and category
fluency)
2 170 0.29 0.24 (20.04, 0.62) 0.19 0.42 1 79
85 102
WAB Construction (calculation) 2 162 0.26 0.23 (20.05, 0.58) 20.26 0.34 1 79
75 124
Oral Praxis 2 74 0.19 0.33 (20.27, 0.65) 20.17 0.83 0 85
68 123
Boston Naming Test 22 1352 0.17 0.30 (0.04, 0.29) 22.24 1.11 0 85
25, 27, 31, 40, 44, 56, 68, 70, 74, 80, 86, 93, 97, 98, 105, 111,
114, 118, 1262128, 134
Token Test 4 182 0.17 0.32 (20.15, 0.49) 20.47 0.78 0 85
29 68 74 129
WAB Construction (drawing) 2 151 20.16 0.23 (20.49, 0.16) 20.17 20.10 0 85
75 124
Category Fluency 43 2481 0.15 0.30 (0.06, 0.24) 25.44 1.35 0 85
25, 28, 30, 31, 40, 44, 60, 68272, 75, 76, 80, 82, 86, 88,
92294, 96298, 100, 101, 105, 1102112, 115, 1182120, 123,
124, 1262131, 134
Phrase Repetition 3 158 20.07 0.30 (20.40, 0.26) 20.66 0.11 0 92
93 97 98
Calculations 4 227 20.06 0.28 (20.33, 0.22) 20.82 0.14 0 92
25 93 97 98
ACE, Addenbrooke’s Cognitive Examination; Max d, maximum effect size; Mean dw, mean weighted effect size; Min d, minimum effect size; N, number of studies contributing to the
effect size; Nfs, fail safe N; %OL, per cent overlap between the Alzheimer’s disease and frontotemporal dementia groups; SD dw, SD of weighted effect size; WAB, Western Aphasia
Battery; WAIS, Wechsler Adult Intelligence Scale (all editions); 95% CI, 95% CI for means.
*Effect sizes weighted by the inverse variance.
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frequently considered to be executive tasks have been included
in other categories (eg, verbal fluency tasks, Wisconsin Card
Sorting Test, Wechsler Adult Intelligence Scale-
Similarities).137 138 None of these met the criteria specified for
discriminating between AD and FTD.
Finally, of the five measures of general ability and
intelligence that were used by the studies included in this
meta-analysis, the MMSE was the only measure that revealed a
large negative effect (see table 10). This indicates that AD
participants were more impaired on this measure than FTD
participants. Despite its widespread use, only those studies
(n = 5) that had pathological confirmation of a patient’s
diagnosis were used in the calculation of this effect size. This
was done in order to avoid a situation where the MMSE was
being used both in group allocation (independent variable) and
as a measure of cognitive performance (dependent variable).
Moderator variables
The influence of four methodological variables (age, years since
diagnosis, education, diagnostic criteria) on the effect sizes was
also examined using Pearson r correlation coefficients and a
WLS multiple regression analysis. ‘‘Diagnostic criteria’’ refer to
the rating given to the quality of the diagnostic criteria that was
used to diagnose AD and FTD (ie, pathological confirmation,
published criteria or other criteria). The mean age, years since
diagnosis, education and diagnostic criteria scores of those
studies that reported this data were firstly correlated with
the weighted mean effect sizes for these studies. Small and
non-significant correlations were observed for age (r =20.01,
n = 90, p = 0.94), years since diagnosis (r =20.10, n = 38, p =
.57), education (r = 0.11, n = 63, p = 0.41) and diagnostic
criteria (r =20.08, n = 94, p = 0.46), indicating that these
variables were not significantly related to the effect sizes. A
WLS multiple regression was additionally performed on the
data from the 22 studies that reported data for all four
variables. The weighted mean effect size for a study was the
dependent variable, the four moderator variables were the
independent variables, and the inverse variance was used as the
weighting variable. The results of this regression analysis are
presented in table 11. The final model was non-significant
(p = 0.98) and accounted for only 23% of the variance.
Therefore, both the correlations and the WLS multiple regres-
sion indicate that age, years since diagnosis, education and
diagnostic criteria did not significantly contribute to the effect
sizes reported in this study. Thus there did not appear to be any
systematic variation in the performance of the AD and FTD
groups on the different tests of cognitive ability as a
consequence of between study differences in these variables,
suggesting that it is acceptable to combine the results of studies
that differed on these methodological variables.
DISCUSSION
Overall, the data for this meta-analysis were obtained from 94
studies that examined the cognitive performance of 2936






Cohen’s dw SD dw (95% CI) Min d Max d Nfs %OL Study references
Beery Developmental Test of Visual
Motor Integration
2 68 20.95 0.39 (21.49, 20.41) 21.00 20.86 8 45 31 86
ACE Visuospatial 2 170 20.58 0.24 (20.91, 20.25) 20.65 20.50 4 62 85 102
Clock drawing tests 4 392 20.53 0.24 (20.76, 20.29) 21.41 20.06 7 67 69 71 92 113
Rey Complex Figure (copy) 25 874 20.43 0.36 (20.57, 20.29) 21.47 0.52 29 73 25, 27231, 42, 68, 78, 86, 88290,
93, 97, 98, 110, 115, 119, 120, 123,
129, 130, 134
Other figure copying tasks 7 551 20.37 0.24 (20.55, 20.19) 20.77 0.41 6 73 40, 44, 69, 70, 92, 105, 126
WAIS Block Design 6 443 20.29 0.32 (20.54, 20.03) 20.84 0.29 3 79 56, 62, 74, 86, 94, 124
WAIS Object Assembly 2 300 0.28 0.26 (20.08, 0.63) 0.21 0.42 1 79 62 94
ACE, Addenbrooke’s Cognitive Examination; Max d, maximum effect size; Mean dw, mean weighted effect size; Min d, minimum effect size; N, number of studies
contributing to the effect size; Nfs, fail safe N; %OL, per cent overlap between the Alzheimer’s disease and frontotemporal dementia groups; SD dw, SD of weighted
effect size; WAIS, Wechsler Adult Intelligence Scale (all editions); 95% CI, 95% CI for means.
*Effect sizes weighted by the inverse variance.






Cohen’s dw SD dw (95% CI) Min d Max d Nfs %OL Study references
Proverb Interpretation 2 111 0.66 0.29 (0.26, 1.05) 0.25 1.00 5 57 69 92
WAIS Comprehension 4 359 0.65 0.31 (0.35, 0.95) 0.40 0.80 9 57 62 72 86 94
Cognitive Estimation Test 2 94 20.51 0.30 (20.93, 20.09) 20.67 20.16 3 67 63 100
Raven’s Progressive Matrices 10 686 20.47 0.28 (20.64, 20.30) 21.75 0.29 14 67 29, 44, 68, 74, 96, 101, 123, 124, 129, 130
WAIS Similarities 6 435 0.37 0.31 (0.12, 0.62) 20.08 0.78 5 73 60 62 72 86 94 126
WCST (errors) 3 109 20.30 0.34 (20.68, 0.08) 20.56 20.20 1 79 31 110 123
WAIS Arithmetic 2 306 0.29 0.25 (20.06, 0.63) 20.22 0.59 1 79 62 94
WAIS Picture Completion 2 308 0.25 0.25 (20.10, 0.59) 0.08 0.53 0 79 62 94
WCST (perseverations) 12 326 0.19 0.41 (20.05, 0.42) 21.16 1.39 0 85 29, 31, 68, 74, 76, 78, 86, 88, 100, 110, 121,
131
WCST (categories) 13 367 0.11 0.40 (20.11, 0.33) 21.41 1.83 0 92 28, 29, 31, 68, 74, 76, 78, 88, 100, 110, 121,
123, 131
WAIS Picture Arrangement 4 479 20.07 0.26 (20.32, 0.19) 20.44 0.25 0 92 44 62 86 94
Judgement of Line Orientation 2 42 20.05 0.46 (20.68, 0.59) 20.26 0.30 0 92 30 111
Max d, maximum effect size; Mean dw, mean weighted effect size; Min d, minimum effect size; N, number of studies contributing to the effect size; Nfs, fail safe N; %OL,
per cent overlap between the Alzheimer’s disease and frontotemporal dementia groups; SD dw, SD of weighted effect size; WAIS, Wechsler Adult Intelligence Scale (all
editions); WCST, Wisconsin Card Sorting Test; 95% CI, 95% CI for means.
*Effect sizes weighted by the inverse variance.
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persons with AD and 1748 persons with FTD. Forty-seven
cognitive tests, which yielded 115 different scores, were used by
more than one study. While the participants with AD were, on
average, older and less educated than the FTD participants, the
two groups were comparable in terms of time since diagnosis.
The lower age of the FTD group is consistent with the fact that
FTD tends to have an earlier onset.14 FTD participants also had
higher MMSE scores than the AD participants. However, this
difference in MMSE scores is likely to reflect the fact that this
measure was originally designed to detect the deficits asso-
ciated with AD (eg, memory, praxis) rather than FTD.
The current meta-analysis found that a wide variety of tests
have been used in research that has examined the cognitive
deficits associated with AD and FTD and that there is
considerable variation in the ability of these measures to
distinguish between AD and FTD. However, in order for a
cognitive test to be useful for differential diagnosis, it was
argued that it must be able to distinguish between the
performance of these two groups (indicated by large effects
and small %OL). There should also be a high degree of
confidence in the accuracy with which the measure distin-
guishes between the two groups (measured by the 95% CI) and
we need to be assured that the conclusions drawn from the
research literature are not systematically biased by the tendency
to publish statistically significant findings (Nfs statistic). When
these three criteria were applied to all of the measures analysed
in this study, there were only 19 out of 115 measures that met
these criteria. More specifically, persons with AD performed
more poorly than those with FTD on 12 of the 19 measures, all
of which assessed orientation, memory or general cognitive
ability. These tests were (in order of discriminative ability): the
ACE orientation subtest, the MMSE, the Beery Developmental
Test of Visual Motor Integration and nine measures of memory
(AVLT recognition and delayed recall scores, Rey Complex
Figure delayed recall score, Recognition Memory Test (words),
WMS Logical Memory per cent retention and delayed recall
scores, ACE memory subtest, WMS Visual Reproduction
delayed recall score and Selective Reminding Test total recall).
In contrast, persons with FTD performed more poorly than
those with AD on seven measures of verbal ability (Graded
Naming Test, Word–Picture Matching, WAB Spontaneous
Speech (fluency), Pyramids and Palm Trees (word score,
picture score), other picture naming tasks and WAB
Comprehension). Importantly, however, there was still between
32% and 48% overlap in the scores of the AD and FTD groups on
all 19 of these measures. This level of overlap suggests that,
even when the most discriminating cognitive tests are used, the
differential diagnosis of AD and FTD remains problematic.
Failure to find tests that clearly discriminate between AD and
FTD confirms previous research which found that the perfor-
mance of AD and FTD participants did not differ significantly
on a large range of tests.27 44 68 72 94 130
The finding that there were nine measures of memory that
were among the most useful for differentiating between AD
and FTD is consistent with research and clinical observations
that memory is differentially affected in AD and FTD.
Numerous previous studies have reported that AD patients
experience greater memory problems than those with
FTD.25 27 28 30 44 66 68 72 78 84 85 90 91 94 112 In contrast, persons diag-
nosed with FTD had more difficulty with tests of verbal ability
and language than those with AD, as demonstrated by eight
large effect sizes in this domain. This supports previous
research which indicated that FTD is associating with language
impairment.5 7 9 In addition, numerous previous studies have
reported that persons with FTD have more difficulty with
executive tasks than AD patients.225 9 11 12 27 67 While executive
tasks would be expected to discriminate between AD and FTD,
given the frontal pathology associated with FTD,9211 this meta-
analysis did not identify any measures of executive functioning
that adequately distinguished between the two groups.
Moreover, other tests that are thought to draw on executive
functions for successful completion,1372139 such as verbal
fluency, Trails and the Stroop tests, failed to meet the current
study criteria.
While there was considerable variation in the effect sizes for
different studies, between study variations in the age of






Cohen’s dw SD dw (95% CI) Min d Max d Nfs %OL Study references
FAB 4 314 0.43 0.25 (0.19, 0.67) 20.12 1.29 5 73 59 104 126 129
Frontal Composite Error Score 2 143 0.29 0.26 (20.07, 0.64) 0.25 0.33 1 79 97 98
FAB (go no go) 2 170 20.13 0.24 (20.46, 0.20) 20.50 0.56 0 92 126 129
Design Fluency 7 306 20.06 0.32 (20.30, 0.17) 20.51 0.61 0 92 25 31 86 93 97 98 131
FAB, Frontal Assessment Battery; Max d, maximum effect size; Mean dw, mean weighted effect size; Min d, minimum effect size; N, number of studies contributing to the
effect size; Nfs, fail safe N; %OL, per cent overlap between the Alzheimer’s disease and frontotemporal dementia groups; SD dw, SD of weighted effect size; 95% CI,
95% CI for means.
*Effect sizes weighted by the inverse variance.






Cohen’s dw SD dw (95% CI) Min d Max d Nfs %OL Study references
MMSE 5 168 20.98 0.37 (21.31, 20.65) 21.29 20.01 19 45 54258
WAIS Verbal IQ 5 427 0.51 0.29 (0.26, 0.77) 0.14 0.92 8 67 31 62 83 94 132
WAIS Full Scale IQ 6 433 0.30 0.31 (0.05, 0.56) 20.23 0.62 3 79 31 62 74 83 86 94
ACE 4 171 20.18 0.34 (20.51, 0.14) 20.70 0.57 0 85 78 99 102 115
WAIS Performance IQ 5 428 0.16 0.29 (20.09, 0.41) 20.56 0.69 0 85 31 62 83 94 132
ACE, Addenbrooke’s Cognitive Examination; Max d, maximum effect size; Mean dw, mean weighted effect size; Min d, minimum effect size; MMSE, Mini-Mental State
Examination; N, number of studies contributing to the effect size; Nfs, fail safe N; %OL, per cent overlap between the Alzheimer’s disease and frontotemporal dementia
groups; SD dw, SD of weighted effect size; WAIS, Wechsler Adult Intelligence Scale (all editions); 95% CI, 95% CI for means.
*Effect sizes weighted by the inverse variance.
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participants, years since diagnosis, years of education and the
diagnostic criteria that were used were not related to the size of
the effects reported by these studies. The finding that years
since diagnosis was not related to the group differences is
surprising given that the symptoms associated with both AD
and FTD vary with the stage of illness, with cognitive
performance declining over time.4 11 12 43 1402142 However, demo-
graphic variables such as age, gender, years since diagnosis and
education were not consistently reported. For example, only
approximately 40% of the studies reported years since
diagnosis. Thus there is the potential for significant but
unreported variation in these variables. Also important is the
fact that mean effect sizes were calculated for each study in
order to complete these analyses. Thus the effect sizes for all of
the individual measures that were used by a given study were
averaged. If a study yielded both small and large effect sizes for
different tests, these were combined to calculate a mean effect
size, which was then correlated with the moderator variables. A
more useful analysis would involve analysing each measure
separately by correlating the effect sizes from all of the studies
that used a particular measure with the age, education and
years since diagnosis data for those studies. However, this was
not possible as the maximum number of studies that used any
given measure was 43. When those studies that did not provide
data for the moderator variables were excluded, the sample size
was reduced to an unacceptably low number (ie, 22). Thus the
current moderator analysis was necessarily limited. Similarly,
current medications and whether depressed participants were
excluded was rarely reported. Therefore, these variables could
not be examined, despite the potential for medications and
depression to affect cognitive performance. It is possible that
these factors contributed to the effect sizes. It is, therefore,
essential that this information is included in future publica-
tions of primary research to allow an accurate and detailed
synthesis of the research findings.
There are a number of limitations to the current meta-
analysis that warrant consideration. Firstly, rating inventories
were not included in the current meta-analysis as they are not
classified as objective cognitive tests.143 144 However, given the
behavioural nature of FTD, a meta-analysis of these beha-
vioural rating scales may yield useful findings. In addition,
assessments of social cognition, personality and empathy
measures, which have been recommended in the differential
diagnosis of dementia,11 13 64 145 did not fall within the scope of
the current meta-analysis but may also be worthy of
consideration.
Secondly, it is important to note that the current meta-
analysis specifically examined AD and FTD. The overlapping
cognitive features of these types of dementia are highlighted by
the fact that few tests clearly discriminated between these two
groups. While greater differences would be expected if the
cognitive performance of the AD and FTD groups were
compared with healthy controls, such an analysis would not
adequately address the question of differential diagnosis.
Thirdly, FTD is described using a variety of terms, which were
combined in the current meta-analysis. This may have
increased the variability in the test performance of the FTD
group. Although it would be desirable to analyse these
subgroups separately, the labels and the diagnostic criteria
that are applied to these subgroups are not used consistently,
thereby precluding a more specific analysis of potential
subtypes. Moreover, more research is needed on each of these
subgroups if they are to be analysed separately.
While this analysis indicates that many test scores do not
clearly discriminate between AD and FTD, there is some
evidence that qualitative aspects of performance may better
distinguish the two groups. For example, a recent study
indicated that the consideration of performance characteristics
and specific error types increased the accuracy of the
differential diagnosis of AD and FTD.33 However, given that
these aspects of performance are often not quantified,
discrimination between AD and FTD is largely reliant on
subjective clinical observations.
Finally, the effect sizes derived from measures used by single
studies were not included in the current meta-analysis.
Technically, a meta-analysis requires two or more studies in
order to aggregate primary research findings.41 One conse-
quence of this is that there may be interesting and innovative
measures that discriminate between groups but are not in
widespread use and were not included in the current analysis.
CONCLUSIONS
In summary, the findings of this meta-analysis suggest that the
neuropsychological tests that best discriminate between AD
and FTD are ACE orientation, ACE memory, recognition and
delayed recall of the AVLT, delayed recall of the Rey Complex
Figure, the words version of the Recognition Memory Test,
WMS Logical Memory (per cent retention and delayed recall),
WMS Visual Reproduction Test (delayed), total recall of the
Selective Reminding Test, Graded Naming Test, Word–Picture
Matching, WAB Spontaneous Speech (fluency), Pyramids and
Palm Trees (word score, picture score), picture naming tasks,
WAB Comprehension, the Beery Developmental Test of Visual
Motor Integration and MMSE. However, it is important to note
that none of the tests showed acceptably low overlap between
the scores of the two groups to confidently make a differential
diagnosis. Therefore, these cognitive tests must be used
cautiously and in conjunction with other diagnostic informa-
tion, such as medical history, behavioural observations,
imaging and information from relatives when making a
differential diagnosis.
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